- TLDR Biotech
- Archive
- Page 1
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | August 29 - September 1, 2024
Novo's Wegovy could prevent death by heart failure & COVID-19, Ipsen sells priority review voucher for $158M, EVOQ Therapeutics lands $2M NIH grant, NIH earmarks $22M for extremophile research, Alnylam heart disease Ph3 succeeds but disappoints, Biosecure Act up for House vote this month.
Biotech & Pharma Updates | August 28 - 29, 2024
J&J aims for "broadest" nipocalimab FDA approval, AbbVie's positive Ph3 Ubrelvy data in migraine prevention, Catalent beats H1 2024 revenue estimates as Novo acquisition approaches, conglomerate Lotte launches biopharma VC division, Qiagen and AstraZeneca partner on companion diagnostics, BioMarin and Repare both cut staff, API manufacturer Global Calcium handed FDA Form 483
Biotech & Pharma Updates | August 27 - 28, 2024
Pfizer, Bayer, and Novartis all sign big partnerships, Astellas' Padcev+Keytruda combo nabs EC approval, Novartis' Leqvio Ph3 data sets stage for label expansion, UK gov launches £400M ($527M) biopharma public-private investment program, NIH launches $270M anti-overdose research program focused on Native American population, Regeneron sues Sandoz over alleged biosimilar patent infringement, Genentech to lay off 93 staffers in SF, EyePoint handed an FDA Warning Letter
Biotech & Pharma Updates | August 26 - 27, 2024
Eli Lilly offers discounted Zepbound, Pfizer officially launches DTC service, a pair of CAR-T cell therapies land China NMPA approval, Navigator Medicines launches with $100M and an in-licensed bispecific antibody, Elektrofi raises $96M of $112M Series C, AstraZeneca's $135M Sweden manufacturing site expansion, trade group BIO pens amicus brief against IRA, Emergent lays off 70 staffers, Sanofi halts China flu vaccine rollouts due to declining potency concerns
Biotech & Pharma Updates | August 25 - 26, 2024
Cigna to (somewhat) ditch AbbVie's Humira for biosimilars in 2025, multiple European Commission approvals, UCB sells Chinese neurology and allergy business for $680M, Diakonos Oncology oversubscribed $11.4M seed raise, MBX Biosciences plans up to $100M IPO, Dexcom launches first OTC wearable glucose biosensor, EcoR1 wants to influence "deeply undervalued" Galapagos, and Lykos woes continue with FDA clinical study probe
Biotech & Pharma Updates | August 22 - 25, 2024
Tome Biosciences burns through $213M with nothing to show, Moderna's RSV vaccine lands European Commission approval, Eli Lilly leads the revenue pack in Q2, Novo Nordisk's Bio Innovation Hub partners with MBC BioLabs, Bayer to lay off 150 employees in Basel, Jazz Pharma seizure med misses Ph3 primary endpoint
Biotech & Pharma Updates | August 21 - 22, 2024
Versant Ventures and Novartis partner to launch Borealis Bioscience, updated COVID shots from Pfizer, BioNTech & Moderna get FDA approval, WuXi Biologics H1 2024 new projects grow but profits fall, Illumina Ventures looks to raise third fund at $300M, Eli Lilly expands antibody discovery pact with Oblique, Liquidia sues FDA over approval exclusivity clause, Tome Biosciences is struggling despite $200M+ raise, Vertex runs marketing foul according to UK's MHRA, Thailand ticks Asia's first new monkeypox strain infection
Biotech & Pharma Updates | August 20 - 21, 2024
GondolaBio launches with $300M and three BridgeBio assets, Retension Pharmaceuticals $10.4M Series A, Roche expands mpox PCR testing acces, Celaid and Tokyo Medical and Dental University stem cell R&D collab, Regeneron's myeloma bispecific rejected by FDA over manufacturing concerns, Windtree Therapeutics running low on cash, Aadi Bioscience decimates R&D department, biopharma execs embrace sustainability but significant hurdles exist, and Astellas employee indicted in China on espionage charges
Biotech & Pharma Updates | August 19 - 20, 2024
Eli Lilly's GIP/GLP-1 golden-goose reduces type 2 diabetes occurrence, J&J nabs FDA approval for first-line mAb+small molecule combo in lung cancer, Pathalys Pharma $105M Series B, Organon buys migraine med Emgality rights from Eli Lilly for multiple countries, Emergent to donate 50k smallpox vaccines, Ozempic/Wegovy use may be linked to suicidal thoughts, Teva & Biogen (separately) sued for alleged pharmacy/PBM kickbacks related to MS meds
Biotech & Pharma Updates | August 18 - 19, 2024
Walgreens and BARDA decentralized clinical trial partnership, BioNTech & MediLink ADC partial clinical hold lifted, MindBio reports positive LSD microdosing Ph2a data in depression, Avidity's $345M fundraise, TYK Medicines planned $74M HKEX IPO, Eli Lilly concludes Morphic takeover, Liquidia's tentative FDA approval collapses stock, and FDA med device recalls aren't really recalls
Biotech & Pharma Updates | August 15 - 18, 2024
AstraZeneca nabs Imfinzi perioperative lung cancer FDA approval, Novo Nordisk invests $221M in new raw materials site, Audax PE buys Avantor's CRO division while also selling healthcare consultancy to Blackstone, Gavi has $500M for mpox shot access, Pfizer & BioNTech's COVID-19/flu vaccine attempt falls short in Ph3, Genentech shutters separate cancer immunology research department
Biotech & Pharma Updates | August 14 - 15, 2024
Medicare reveals first drug price negotiations, Bavarian Nordic stock nearly doubles on mpox global health emergency concerns, Zealand Pharma searches for commercial partner for their obesity med, Abata (Treg) lands strategic investment from BMS, Bayer's restructuring (allegedly) ain't slowing down BD efforts, SIGA Tpoxx antiviral misses primary endpoint, the L's keep stacking for Lykos as they cut 75% of their staff